Guggenheim initiated coverage of Pharvaris (PHVS) with a Buy rating and $32 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials
- Pharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials
- Pharvaris’s Strategic Advancements and Clinical Progress Justify Buy Rating
- Pharvaris presents data supporting ongoing clinical development of deucrictibant
- Pharvaris: Strong Buy Rating Backed by Clinical Progress and Financial Stability